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SUMMARY
Aim: To evaluate efficacy and safety of oral beclometa-
sone dipropionate (BDP) when added to 5-ASA in the
treatment of patients with active ulcerative colitis.
Methods: In a 4-week, placebo-controlled, double-blind
study, patients with extensive or left-sided mild to
moderate active ulcerative colitis were randomized to
receive oral 5-ASA (3.2 g ⁄ day) plus BDP (5 mg ⁄ day)
or placebo. Clinical, endoscopic and histologic features,
and haematochemical parameters were recorded at
baseline and at the end of the study.
Results: One hundred and nineteen patients were
enrolled and randomly treated with BDP plus 5-ASA
(n ¼ 58) or placebo plus 5-ASA (n ¼ 61). Both
treatment groups showed a statistically significant
decrease of disease activity index (DAI) and histology
score at the end of treatment (P ¼ 0.001, each). DAI
score was lower in the BDP group than in the placebo
group (P ¼ 0.014), with more patients in clinical
remission in the BDP group (58.6% vs. 34.4%, P ¼
0.008). Serum cortisol levels significantly decreased in
BDP group vs. baseline (P ¼ 0.002), but without signs
of pituitary-adrenal function depletion. A low incidence
of adverse events was observed in both groups.
Conclusions: Oral BDP in combination with oral 5-ASA
is significantly more effective than 5-ASA alone in the
treatment of patients with extensive or left-sided active
ulcerative colitis.
INTRODUCTION
Glucocorticosteroids (GCS) therapy is a well established
approach for active ulcerative colitis,1, 2 but their
prolonged use is limited by the risk of systemic steroid-
related adverse effects.3 In recent years, greater efforts
have been spent to develop a new family of GCS with the
same efficacy as traditional GCS, but with a more
favourable safety profile. Beclometasone dipropionate
(BDP) displays a prompt and potent topical anti-
inflammatory activity, but its systemic activity is
limited.4 BDP has the advantage of reducing systemic
side-effects, such as Cushing-like syndrome and sup-
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pression of the hypothalamic–pituitary–adrenal axis,
which are evident with conventional corticosteroid
treatment.5, 6 The reduction in side-effects following
topical delivery of BDP is largely due to the high degree
of first pass metabolism following absorption from the
lower gastrointestinal tract.7 The efficacy of rectally
administered BDP is well demonstrated and comparable
to that of conventional GCS8–10 or aminosalicy-
lates.11, 12
Recently, an oral controlled-release preparation of
BDP (Clipper tablets; Chiesi Farmaceutici S.p.A., Italy)
has been developed with an acid-resistant methacry-
late film coating (Eudragit L100 ⁄ 55) that prevents
the tablets from dissolving in the stomach and a
modified release core of hydroxypropyl methylcellu-
lose (Methocel K4M) that dissolves at pH values
lower than 6.0, so the drug is released in the distal
small bowel and during the passage throughout the
colon.13 Compared with the two different pH
dependent formulations of oral budesonide, the other
recently launched GCS with low systemic bioavaila-
bility, oral BDP, could be considered similar to the
controlled ileal release formulation for the treatment
of active ileocaecal Crohn’s disease, in which the
drug is released at a pH above 5.5 and 50–80% of
an oral dose is absorbed in the ileum and proximal
colon.14 In this other formulation, budesonide is
released from an Eudragit coating when pH exceeds
6.4. In this context it appears relatively ineffective in
patients with active Crohn’s disease confined to the
left colon and rectum15 in whom colonic pH may be
low.16 BDP plasma concentrations following the oral
administration of a 5-mg tablet13 and also following
single oral dosing and two single rectal administra-
tions (enemas and suppositories) were found to be
very low.17 In patients who had undergone terminal
ileostomy, a single oral administration of BDP 5 mg
tablet was followed by the presence of BDP and its
major metabolite (beclometasone 17-monopropionate)
in ileostomy effluents, supporting a significant release
of BDP at the site of action.18 The therapeutic
efficacy of oral BDP in the treatment of active
ulcerative colitis appears to be comparable to
that of 5-ASA, as demonstrated in previous
studies.19, 20
The present study was performed to compare efficacy
and safety of oral BDP with placebo as adjunctive




Out-patients of both sexes, aged at least 18 years,
with a definite diagnosis of extensive or left-sided
active ulcerative colitis were eligible for inclusion. At
entry patients had a disease activity index (DAI) score
ranging from 3 to 10 points. DAI is a 12-point
scoring system that includes endoscopic and clinical
parameters (Table 1).21 Patients with a DAI score < 3
were considered in clinical remission, 3–6 with mild,
7–10 moderate, and > 10 severe activity of the
disease.
Patients with a new diagnosis of ulcerative colitis,
severe ulcerative colitis or in clinical remission on the
basis of DAI score were excluded from the study. Other
exclusion criteria included severe renal or hepatic
failure, diabetes mellitus, gastroduodenal disease, heart
failure, severe or moderate hypertension, neoplastic
disease, psychosis, alcohol and drug abuse, pregnancy
or lactation. Patients receiving corticosteroid treatment
for a period of 1 month prior to study initiation or
5-ASA at a dosage > 3.2 g ⁄ day or sulfasalazine at a
dosage > 2 g ⁄ day for 2 weeks preceding study entry
and during the trial were also excluded.
Table 1. Disease activity index (DAI), a qualitative rating scale
with four subscales
Score
Stool frequency (daily average)
Normal 0
1–2 stools ⁄ day > normal 1
3–4 stools ⁄ day > normal 2
> 4 stools ⁄ day > normal 3
Rectal bleeding
None 0







Exudation, spontaneous bleeding 3





Maximum score ¼ 12.
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The study was conducted according to the Declaration
of Helsinki and was ap proved by local Ethics Commit-
tees. Written informed consent was obtained from each
patient prior to study initiation.
Study drugs
BDP, the corresponding placebo and a commercially
available preparation of 5-ASA (Asacol 400 mg tablets;
Bracco Industria Chimica, Italy) were supplied by Chiesi
Farmaceutici S.p.A. (Parma, Italy). BDP 5 mg tablets
and placebo tablets were identical in appearance and
were provided in identical glass bottles. Patients were
randomly assigned to receive one tablet of BDP 5 mg or
one tablet of placebo administered once daily early in
the morning (8–9 am). Eight tablets per day of 5-ASA
400 mg were also administered to both treatment
groups for the whole study period.
Methods and assessment of the treatment results
The study was conducted according to a randomized,
double-blind, placebo-controlled design. At each parti-
cipating centre, treatment allocation was made from
blocks of four numbers produced by a computer-
generated randomization list (SAS programme, version
6.12). The patients were treated for 4 weeks and
compliance was checked by counting residual study
medication at the end of the treatment period. Patients
were considered compliant if they had taken at least
75% of the medication.
A screening visit (visit 1) was planned between a
maximum of 15 days and a minimum of 3 days before
entry to assess eligibility and to register clinical
symptoms of patients (number of movements, quality
of life, presence of blood in the stools) and to obtain
written informed consent. To determine activity and
extent of the disease, all eligible patients were graded
with clinical findings and underwent a pancolonoscopy
at baseline (visit 2) and after 4 weeks of treatment (visit
4). Endoscopic activity was graded according to Baron’s
criteria.22 A clinical control was performed after the first
2 weeks of treatment (visit 3) when the study medica-
tion for the next 2 weeks of treatment was also
assigned. At the end of the treatment period, patients
were classified as responders if their DAI score was
reduced by at least 3 points compared to baseline.23
To establish the histologic activity of ulcerative colitis,
mucosal biopsy specimens were obtained from each
segment of the colon (ascending, transverse, descending
and sigmoid) and rectum, and always from the most
severely affected area in each segment. The degree of
inflammation in the histological specimens was graded
according to Truelove & Richard’s criteria.24
The primary outcome measures for efficacy were daily
stool frequency, blood in stools, subjective sense of well-
being, and mucosal appearance at colonoscopy. Secon-
dary efficacy outcome measures were histology and
erythrocyte sedimentation rate (ESR).
Blood chemistry tests (haematological, liver and
renal function tests, plasma glucose, electrolytes) were
performed on all patients at baseline and at the end of
the treatment. Blood pressure, heart rate and weight
were monitored at baseline and after 4 weeks.
Adverse events were recorded throughout the study
period.
The primary outcome measure for safety was the effect
of oral BDP on endogenous cortisol production, which
was assessed by measuring morning serum cortisol
levels and by monitoring of signs of pituitary-adrenal
function (leg oedema, Cushing-like syndrome, hyper-
tension, diabetes). Plasma samples were drawn at
08.00–10.00 hours, following an overnight fast (nor-
mal range 5–25 lg ⁄ dL).25 Samples were frozen at
)20 C and evaluated in a centralized independent
laboratory for the determination of serum cortisol levels.
A high-performance liquid chromatography method
was used.
Statistical analysis
The sample size was calculated on the assumption that
65% of patients would respond to BDP treatment and
40% would respond to placebo. Sixty-two patients were
assigned to each treatment group when a two-tailed test
was employed with a ¼ 0.05 and 1-b ¼ 0.80.
Student’s t-test and Wilcoxon’s rank sum test were
used to compare the two treatment groups at baseline.
The intention-to-treat (ITT) population included all
recruited patients with any evidence of having received
at least one dose of study medication. The last
observation carried forward (LOCF) method was applied
to deal with missing data.
The Wilcoxon Signed rank test was performed to
compare the changes from baseline of the efficacy
variables in the within treatment analysis, while the
Wilcoxon rank sum test was used to verify the
differences between the two groups.
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Changes in laboratory values were analysed using the
t-test for paired data. The incidence of adverse events
was compared using the Chi-squared or the Fischer’s
exact test.
RESULTS
One hundred and nineteen patients were enrolled in 11
Italian centres. A further five patients were not
recruited because of the end of the enrolment period.
Patient characteristics of the two treatment groups at
study entry were similar for demographic parameters,
smoking habits, extent, severity and duration of the
disease, and the mean 5-ASA daily dosage administered
before entry (Table 2).
Fourteen patients (11.8%) did not complete the study:
two (1.7%) in the BDP group (one for clinical worsening
and one due to an adverse event) and 12 (10.1%) in the
placebo group (nine because of clinical worsening and
three due to adverse events) (Figure 1). No patient was
considered non-compliant.
Efficacy of oral BDP on colitis
ITT analysis demonstrated that both treatment groups
reached a significant reduction (P ¼ 0.001) in the DAI
score, with a significant difference (P ¼ 0.014) in
favour of the BDP group compared to the placebo group
(Table 3).
The percentage of patients in clinical remission was
higher in the BDP group (58.6%, n ¼ 34) compared to
the placebo group (34.4%, n ¼ 21) and the difference
between the two groups was statistically significant
(P ¼ 0.021) (Figure 2). Only one patient in the BDP
Figure 1. Disposition of patients.
Chi-squared: P ¼ 0.021 between
treatments.
Table 2. Demography and disease history in BDP group and in
placebo group at study entry
BDP (n ¼ 58)
Placebo
(n ¼ 61)
Age (year)* 43.1 (14.5) 44.7 (13.1)
Weight (kg)* 68.1 (12.2) 70.4 (12.2)
Height (cm)* 168.6 (7.9) 168.3 (8.5)
Male 41 (71) 43 (70)
Smoker 5 (9) 6 (10)
Alcohol consumption 12 (21) 12 (20)
Coffee consumption 31 (53) 32 (52)
Diagnosis
Left ulcerative colitis 38 (66) 47 (77)
Pancolitis 20 (34) 14 (23)
5-ASA daily dosage
before study entry (g)*
1.72 (0.71) 1.78 (0.79)
Disease activity (DAI score)
Mild 14 (24) 12 (20)
Moderate 44 (76) 49 (80)
SBP (mmHg)* 127 (11) 124 (11)
DBP (mmHg)* 77 (6) 76 (7)
Heart rate (bpm)* 78 (8) 77 (8)
Data are n (%) unless otherwise indicated; * mean (s.d.).
DAI ¼ disease activity index; SBP ¼ systolic blood pressure; DBP ¼
diastolic blood pressure.
Table 3. Disease activity index in BDP group (n ¼ 58) and in
placebo group (n ¼ 61) at baseline and after 4 weeks of
treatment
Baseline 4 weeks P
BDP + 5-ASA 6.3 (1.9) 2.6 (2.6)* 0.001
Placebo + 5-
ASA
6.4 (1.5) 3.4 (2.2)* 0.001
Data expressed as a mean (s.d.); * P ¼ 0.014 between treatments.
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group, but nine patients in the placebo group withdrew
from the study due to treatment inefficacy (P ¼ 0.01
between treatments).
The DAI variables were also singularly evaluated
(Table 4) and a more significant improvement in rectal
bleeding and sense of well-being was noted in the BDP
group compared to the placebo group (P ¼ 0.017 and
P ¼ 0.005, respectively).
The endoscopic score was reduced in both groups after
4 weeks: a normalization of intestinal mucosa was
observed in 18 out of 58 (31%) patients in the BDP
group and 10 out of 61 (16%) patients in the placebo
group. Histological assessment showed a significant
improvement vs. baseline in both groups (P ¼ 0.001,
each). No significant difference in the between treat-
ment analysis was observed.
Reflecting an improvement in inflammatory status,
mean ESR vs. baseline was significantly reduced in the
BDP group (from 19.2 ± 15.2 to 14.2 ± 13.1,
P ¼ 0.001) and not in the placebo group (from
17.8 ± 13.3 to 18.6 ± 17.6), with a significant differ-
ence between treatments (P ¼ 0.05) at the end of the
study period. In comparison with the placebo group a
significant increase of erythrocytes (P ¼ 0.015,
P ¼ 0.049 between treatments), haemoglobin
(P ¼ 0.001, P ¼ 0.001 between treatments) and
haematocrit (P ¼ 0.001, P ¼ 0.001 between treat-
ments) was also observed in the BDP group, in line with
the reduced rectal bleeding.
Safety results and effect on adrenal function
No changes in blood pressure, heart rate and weight
were detected in either treatment groups at the end of the
treatment period. There were no modifications in blood
chemistry, liver and renal function tests and electrolytes.
A slight but significant decrease of plasma glucose from
88.9 to 84.2 mg ⁄ dL (P ¼ 0.004) and of platelet count
from 276.3 to 262.3 109 ⁄ L (P ¼ 0.036) was observed.
Figure 2. Disease activity index (DAI)
evaluation in the BDP group (n ¼ 58) and
in the placebo group (n ¼ 61) at baseline
and after 4 weeks of treatment.
Table 4. Disease activity index variables at baseline and after
4 weeks of treatment in the BDP group (n ¼ 58) and in the
placebo group (n ¼ 61)
Baseline 4 weeks P
BDP + 5-ASA
Stool frequency 2.0 (0.8) 0.8 (1.0) 0.001
Rectal bleeding 1.5 (0.8) 0.4 (0.6)* 0.001
Sense of well-being 1.0 (0.7) 0.4 (0.6)** 0.001
Colonoscopy 1.8 (0.5) 1.0 (0.9) 0.001
Placebo + 5-ASA
Stool frequency 2.0 (0.7) 1.0 (0.9) 0.001
Rectal bleeding 1.5 (0.7) 0.6 (0.7) 0.001
Sense of well-being 1.0 (0.6) 0.7 (0.5)
Colonoscopy 2.0 (0.5) 1.1 (0.8) 0.001
Data expressed as a mean (s.d.); score 0–3; * P ¼ 0.017 between
treatments; ** P ¼ 0.005 between treatments.
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Mean morning serum cortisol levels were assessed in
53 out of 58 patients in the BDP group and in 51 out of
61 patients in the placebo group, they were significantly
decreased in the BDP group at the end of the treatment
period (P ¼ 0.002), but were still within the normal
range. Four out of 53 BDP-treated patients (7.5%)
showed levels less than the lower reference limit of
5 lg ⁄ dL, but no signs of pituitary-adrenal function
depletion, such as leg oedema or Cushing-like syndrome
were observed.
Adverse events
Two out of 58 (3.4%) patients in the BDP group and
four out of 61 (6.5%) in the placebo group experienced
adverse events. None of the adverse events recorded
was serious and treatment was suspended in one
patient in the BDP group (constipation) and three
patients in the placebo group (facial and abdominal
swelling, seizures, pruritus). The adverse events recor-
ded were defined as doubtfully related to the test
treatments.
DISCUSSION
Previous studies have demonstrated that BDP adminis-
tered as controlled-release tablets produces a positive
response in patients with active mild to moderately
severe ulcerative colitis19 and is as effective as oral
5-ASA.20 Many ulcerative colitis patients experience
relapses not always successfully treated with oral 5-ASA
alone. In these patients, in order to reduce the mucosal
inflammation and to improve the quality of life, it is
useful to add systemic or local corticosteroid therapy.26
Its limited systemic activity means that BDP has the
advantage of reduced systemic side-effects such as
suppression of the hypothalamic–pituitary–adrenal axis
and Cushing-like syndrome, which are evident with
conventional GCS. The two treatment groups were well
balanced for demographic parameters, severity and
duration of the disease, and the 5-ASA daily dosage
taken before study entry. Considering the lack of
universally accepted efficacy parameters in ulcerative
colitis trials, the widely employed DAI of Sutherland
et al.21 was used as the main outcome evaluation. The
duration of treatment (4 weeks) is considered to be
sufficient for therapeutic response in patients with
active disease.27
Due to the high 5-ASA dosage (3.2 g ⁄ day) adminis-
tered in all included patients throughout the study
period, even in placebo-treated patients, we observed an
improved inflammatory status in the colon and rectum,
which translated into a significantly decreased DAI
score (P < 0.001) vs. baseline.
As adjunctive therapy to oral 5-ASA, however, oral
BDP has been found to significantly improve clinical
symptoms and mucosal appearance in patients with
active ulcerative colitis. After a 4-week treatment
period, a significant improvement in the disease activity
associated with a higher percentage of patients in
clinical remission in the BDP group (58.6% compared
with 34.4% in the placebo group) was achieved. In
favour of the BDP group there was also a significant
difference between treatments with regard to the
number of withdrawn patients due to the treatment
inefficacy. The significant reduction of ESR and rectal
bleeding in BDP-treated patients also confirmed the
positive response of the inflammatory process.
Decreased loss of blood in stools reflected a significant
increase in erythrocytes count, haemoglobin and
haematocrit. The histopathologic scores were signifi-
cantly reduced compared with baseline in both treat-
ment groups.
Even in combination with oral 5-ASA, the good safety
profile of oral BDP shown in previous studies has been
confirmed.19, 20 Although there was a significant
reduction in serum cortisol levels at the end of
treatment, the mean value remained within the normal
range, and, even though four patients had serum
cortisol levels below the lower reference limit, no
clinical signs or adverse reactions related to adrenal
depletion were recorded. Also the incidence of adverse
events was low, with no serious side-effects recorded.
In conclusion, oral BDP controlled-release formula-
tion at a dosage of 5 mg ⁄ day, as adjunctive therapy
to 5-ASA, was found to be significantly more
efficacious compared with oral 5-ASA alone in the
treatment of mild to moderately severe active ulcer-
ative colitis, and is generally well tolerated without
inhibitory effects on endogenous serum cortisol. Due
to the good safety profile shown by oral BDP in the
4-week treatment of active ulcerative colitis, further
studies to assess the efficacy and interference with
hypothalamic–pituitary–adrenal function, when long-
term use is proposed, will be an important area for
investigation.
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